In This Article:
LONDON, Ontario and BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for Type 1 diabetes (T1D), today announced the appointment of Ross Haghighat as Chair of the Board. With a proven track record in driving successful innovations, strategic growth and mergers and acquisitions in the biotechnology and life sciences sectors, Mr. Haghighat brings a wealth of financing and deal experience to Sernova’s Board and leadership team.
Jonathan Rigby, President and CEO of Sernova, stated, “We are thrilled to welcome Ross Haghighat as our new Chair of the Board. His deep industry knowledge and visionary leadership make him the perfect fit to guide Sernova as we advance our pipeline of transformative therapies. His appointment underscores our commitment to fulfilling our mission of bringing solutions to patients in need.”
Mr. Haghighat has over three decades of experience in founding, funding, and scaling technology ventures in healthcare, an asset that will support Sernova’s strategic direction and innovation objectives. He is known for his long-term strategic insights and the execution thereof, as evidenced in successfully driving multiple companies to achieve significant milestones and growth.
Commenting on his appointment, Mr. Haghighat remarked, “I am honored to join Sernova and support its journey toward approval of its Cell Pouch bio-hybrid organ as a functional cure for T1D. The company’s pioneering work in cell therapy is truly inspiring. I look forward to working with Jonathan, the Board, and the entire team to advance Sernova’s mission and deliver on our goals.”
Sernova’s Board of Directors expressed unanimous support for Mr. Haghighat’s appointment.
The Company is also pleased to report that it will complete the continuance of its corporate jurisdiction into British Columbia this week and the Company will become a corporation existing under the Business Corporations Act (British Columbia). The continuance of the Company’s corporate jurisdiction (which was formerly under the Canada Business Corporations Act) was approved by a special resolution of shareholders at the Company's annual and special general meeting held on January 10, 2025.
In connection with the continuance and to better communicate the nature of the business, the Company has changed its name from Sernova Corp. to Sernova Biotherapeutics Inc. No changes are expected in the Company’s ticker symbols.